A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET). This study aims to investigate the safety profiles of sunitinib through data mining of the US...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2024-07-01
|
| Серія: | Frontiers in Pharmacology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1407709/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|